SFTSV Non-structural Protein Triggers Inflammasome Activation via DPP9 Complex Disruption

Study Background and Research Question

Severe fever with thrombocytopenia syndrome (SFTS), caused by the tick-borne SFTS virus (SFTSV), is a viral hemorrhagic fever with high mortality rates up to 30% (source: paper). Innate immunity, specifically via inflammasome complexes, plays a critical role in sensing and responding to such viral infections. NLRP1 and CARD8 are pattern recognition receptors capable of assembling inflammasomes upon detection of pathogen- or danger-associated signals. However, the precise mechanisms by which viral factors trigger activation of these inflammasome components have remained incompletely defined. The central research question addressed by Liu et al. (2025) is: How does SFTSV manipulate host inflammasome activation through molecular interaction with dipeptidyl peptidases and their regulatory complexes?

Key Innovation from the Reference Study

The study by Liu and colleagues provides the first mechanistic evidence that the SFTSV non-structural protein (NSs) activates both NLRP1 and CARD8 inflammasomes by directly disrupting the DPP9-mediated inhibitory ternary complex (source: paper). The authors show that SFTSV NSs binds to the function-to-find (FIIND) domains of NLRP1 and CARD8, outcompeting DPP8/9 for binding, and also promotes the degradation of DPP8 and DPP9 proteins. This dual mechanism destabilizes the inhibitory complex, allowing release and activation of the C-terminal (CT) fragments of NLRP1 and CARD8, and subsequent inflammasome assembly.

Methods and Experimental Design Insights

Liu et al. applied a combination of cell biology, molecular interaction, and infection assays to dissect the molecular interplay between SFTSV NSs, DPP8/9, and the inflammasome components. Key elements of their design include:

• Infection models: Primary human keratinocytes and macrophages were infected with SFTSV to assess tissue-specific inflammasome activation.
• Protein interaction studies: Co-immunoprecipitation and domain-mapping experiments were used to determine the binding specificity of NSs for the FIIND domains of NLRP1 and CARD8.
• Complex stability assessments: The integrity of the DPP8/9-NLRP1/CARD8 ternary complex was evaluated following NSs expression and SFTSV infection.
• Functional readouts: Inflammasome activation was monitored via detection of caspase-1 activation, IL-1β and IL-18 secretion, and pyroptotic cell death.
• Gene knockout approaches: CARD8 deletion models were used to assess the impact on SFTSV replication.

Protocol Parameters

• Virus infection assay | SFTSV MOI 0.5–1 | primary keratinocytes, macrophages | sufficient for inflammasome activation and viral replication studies | paper
• Co-immunoprecipitation | 1–2 mg total protein per sample | protein–protein interaction mapping | optimal for detecting NSs-FIIND domain association | paper
• IL-1β/IL-18 ELISA | 50–100 μL supernatant per assay | inflammasome functional readout | quantifies cytokine secretion post-infection | paper
• CARD8 knockout | CRISPR/Cas9-mediated gene editing | macrophage cell lines | tests the role of CARD8 in viral replication control | paper

Core Findings and Why They Matter

The discovery that SFTSV NSs triggers NLRP1 and CARD8 inflammasome activation via disruption of the DPP9-mediated ternary complex represents a significant advance in understanding viral subversion of host immunity. At baseline, the FIIND domains of NLRP1 and CARD8 interact with DPP8/9, maintaining these inflammasome sensors in an autoinhibited state. SFTSV infection leads to:

• Direct competition of NSs for FIIND binding, weakening DPP8/9’s inhibitory hold.
• Promoted degradation of DPP8 and DPP9, further destabilizing the complex.
• Release of NLRP1 and CARD8 CT fragments, initiating inflammasome assembly, caspase-1 activation, and cytokine secretion.
• Evidence that CARD8 deletion increases SFTSV replication, indicating CARD8’s role in restricting viral propagation.

These findings bridge inflammasome biology with the molecular pharmacology of dipeptidyl peptidases, which have previously been studied primarily in cancer and immunology contexts (source: paper).

Comparison with Existing Internal Articles

Several internal resources discuss the role of dipeptidyl peptidase inhibitors, such as Talabostat mesylate (PT-100), in modulating immune responses and the tumor microenvironment. For example, "Talabostat Mesylate: From Mechanistic Insight to Translational Impact" explores how dual DPP4 and FAP inhibition can enhance T-cell immunity and stimulate hematopoiesis via G-CSF, providing a mechanistic rationale for targeting these enzymes in cancer workflows. Similarly, "Mechanistic Precision and Strategic Guidance" addresses the emerging relevance of inflammasome regulation via the DPP family, providing a translational context for the findings of Liu et al. Although the present study is focused on viral immunity rather than cancer, the shared molecular checkpoint—DPP8/9-mediated inhibition—underscores the broader biological and therapeutic potential of DPP family inhibitors for modulating immune and inflammatory states (source: internal_article).

Why this cross-domain matters, maturity, and limitations

This study’s mechanistic focus on DPP8/9-mediated regulation of inflammasome sensors is directly relevant to the field of tumor microenvironment modulation, where DPP4 and FAP inhibitors such as Talabostat mesylate have shown promise in preclinical models of cancer immunotherapy. However, direct extension from viral inflammasome activation to cancer immunomodulation must be approached cautiously, as the microenvironmental cues and downstream consequences differ. While both domains benefit from understanding DPP-mediated regulatory checkpoints, the translational maturity of DPP inhibition is further advanced in oncology than in antiviral or inflammatory contexts (source: internal_article).

Limitations and Transferability

Although the study provides robust molecular evidence for NSs-mediated DPP8/9 complex disruption and inflammasome activation, several limitations should be noted:

• The specificity of NSs interactions with DPP8 versus DPP9 was not exhaustively dissected.
• All main findings were generated in cell-based models; validation in in vivo infection models is warranted.
• The broader physiological consequences of chronic or transient disruption of DPP8/9-inflammasome checkpoints, especially outside acute infection, remain to be determined.

For researchers considering transfer of these findings to other disease models, it is essential to account for cell type differences, the context-dependence of inflammasome activation, and potential off-target consequences of DPP family inhibition (workflow_recommendation).

Research Support Resources

To facilitate further study of DPP-mediated regulation in both immunology and oncology workflows, researchers may consider using Talabostat mesylate (SKU B3941), a well-characterized, orally active inhibitor of DPP4 and FAP. This compound has been extensively profiled for its ability to modulate the tumor microenvironment, enhance immune responses, and stimulate hematopoiesis via G-CSF induction in preclinical cancer models (source: internal_article). When applying such inhibitors in the context of inflammation or infection, it is recommended to optimize assay conditions for each biological system and to carefully monitor off-target effects (workflow_recommendation). For detailed product specifications and protocols, visit the APExBIO resource page.